Alumis Inc. (ALMS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients with a high interferon gene signature, a subgroup it plans to emphasize in future development discussions with regulators.
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and acquisition potential.
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets
Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psoriasis data and pipeline potential. Envudeucitinib demonstrated efficacy comparable to JNJ's newly approved Icotyde, with 74% PASI 75 and 59% sPGA 0/1 at week 16. ALMS targets NDA submission for envudeucitinib in 2H 2026, with additional data in psoriatic arthritis and SLE expected in 2026.
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise
Alumis Inc. surged 95% after reporting strong Phase 3 results for lead candidate envudeucitinib in moderate-to-severe plaque psoriasis. Envudeucitinib demonstrated high efficacy for an oral agent, with two-thirds achieving PASI 90 and over 40% reaching complete clearance by Week 24. ALMS announced a $175 million public offering to fund regulatory and clinical advancement, with a 2026 NDA submission targeted.
Alumis Stock Hits Record High on Psoriasis Drug Trial Results
Biotech stock Alumis Inc (NASDAQ:ALMS) is skyrocketing today, up 107.9% at $17.28 at last glance, after the Johnson & Johnson (JNJ) rival announced its plaque psoriasis drug, envudeucitinib, met all of its primary and secondary endpoints in both of its phase three trials.
Alumis skin disease drug meets main goal of two late-stage trials
Alumis said on Tuesday its experimental pill met the main goal in two late-stage studies in patients with a type of skin disease.
Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript
Alumis Inc. (NASDAQ:ALMS ) Stifel Virtual Immunology and Inflammation Forum September 16, 2025 12:30 PM EDT Company Participants Martin Babler - President, CEO & Chairman Conference Call Participants Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Alexander Thompson Stifel, Nicolaus & Company, Incorporated, Research Division We're back now with Alumis for a fireside chat. We have CEO, Martin Babler; and CFO, John Schroer for a fireside.
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high selectivity and minimal off-target effects, potentially positioning it as a better alternative to the approved TYK2 inhibitor, Sotyktu. Despite strong midstage trial data and a solid cash runway, the highly competitive market and recent IPO status present significant investment risks.
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
